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Cytotoxic T lymphocyte (CTL) responses against the HIV Gag protein are associated with lowering 
viremia; however, immune control is undermined by viral escape mutations. The rapid viral mutation 
rate is a key factor, but recombination may also contribute. We hypothesized that CTL responses 
drive the outgrowth of unique intra-patient HIV-recombinants (URFs) and examined gag sequences 
from a Kenyan sex worker cohort. We determined whether patients with HLA variants associated 
with effective CTL responses (beneficial HLA variants) were more likely to carry URFs and, if so, 
examined whether they progressed more rapidly than patients with beneficial HLA-variants who 
did not carry URFs. Women with beneficial HLA-variants (12/52) were more likely to carry URFs than 
those without beneficial HLA variants (3/61) (p < 0.0055; odds ratio = 5.7). Beneficial HLA variants 
were primarily found in slow/standard progressors in the URF group, whereas they predominated in 
long-term non-progressors/survivors in the remaining cohort (p = 0.0377). The URFs may sometimes 
spread and become circulating recombinant forms (CRFs) of HIV and local CRF fragments were over-
represented in the URF sequences (p < 0.0001). Collectively, our results suggest that CTL-responses 
associated with beneficial HLA variants likely drive the outgrowth of URFs that might reduce the 
positive effect of these CTL responses on disease progression.
Millions of patients are already receiving expensive, life-long anti-HIV treatment, and millions more 
will require treatment because of the continued spread of HIV-1, particularly in resource-poor settings 
worldwide (www.unaids.org). The solution to this epidemic will require the development of a preventive 
vaccine and, potentially, therapeutic vaccines1. However, producing a safe and effective HIV-1 vaccine 
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remains an elusive goal, and elucidating basic virus-host interactions is critical to improving vaccine 
strategies.
The immune system never successfully clears HIV-1 during the course of natural infection; however, in 
a few patients, the virus can be contained for decades through cytotoxic T lymphocyte (CTL) responses2. 
The protective CTL responses in these patients, who are known as long-term non-progressors (LTNPs), 
are primarily restricted by a few relatively rare human leukocyte antigen (HLA) variants, although not all 
patients with these HLA variants become LTNPs2–5. In addition, CTL responses against the HIV-1 capsid 
protein p24Gag are associated with lower mean viral loads in patients regardless of HLA restriction6. 
Because lower viral loads are associated with slower disease progression and lower transmission risk, 
these CTL responses improve the individual quality of life and limit the spread of the HIV-1 epidemic. 
However, the characteristics of an efficient CTL response and the reason why disease progression is not 
delayed in all patients with protective HLA variants remains unclear.
All CTL responses can select for mutations within or flanking CD8 epitopes, which allows HIV-1 to 
escape CTL recognition and prevents infected cells from being killed. These mutations may affect HLA 
binding, T cell receptor contact sites and/or antigen processing2,7–11. This evasion of immune responses 
is so advantageous that positive selection of escape mutations drives HIV-1 evolution within hosts12.
Escape mutations may occur relatively slowly and one-by-one in individual viruses over time or they 
may spread rapidly en-bloc through the HIV-1 population by recombination. Recombination occurs 
when the viral reverse transcriptase (RT) protein switches between the two HIV-1 RNA genomes and 
generates a recombinant DNA strand during transcription. In vitro studies have demonstrated that at 
least 2.8 crossovers occur per replication cycle per genome13; thus, the HIV-1 recombination rate per rep-
lication likely exceeds the RT mutation rate (3.4 × 10−5 mutations per nucleotide per cycle)14–16. However, 
because most infected cells carry only one integrated provirus17 the vast majority of co-packaged RNA 
genomes share a single provirus as a common ancestor. Therefore most recombination events occur 
between nearly identical sequences and are difficult to detect. Recombinants between more distantly 
related viruses are often not as fit as the parent viruses and selection in natural infections likely primarily 
favours the outgrowth of such recombinant viruses if recombination results in fitness gain18,19.
Most phylogenetic analyses of HIV-1 do not accommodate recombination because it violates the 
assumption of phylogeny inference of descent from a common ancestor16,20. However, recombination has 
been observed in acute HIV infection through visual inspection and/or comparisons with the inferred 
founder virus sequence19,21. This observation has been possible because one or a small number of viruses 
typically causes initial infection19,21–23. The risk of superinfection, i.e., a later infection by a second HIV 
strain, is similar to that of initial infection during the first 6 months and subsequently decreases by 
approximately half24,25 but can be difficult to recognize if the superinfecting HIV strain belongs to the 
same subtype as the HIV strain that initially infected the patient.
By contrast, recombination between two different HIV subtypes is easy to identify and the effect of 
recombination between subtypes is evident on the epidemiological scale. Most circulating HIV-1 strains 
belong to the main (M) group, which is divided into 10 homogeneous subtypes (labelled alphabetically), 
two sub-subtypes (e.g., HIV-A1 and HIV-A2) and several circulating recombinant forms (CRFs) of two 
or more subtypes (n > 60). Although the number of CRFs far exceeds the number of pure subtypes/
sub-subtypes, the majority of HIV-infected people worldwide remain infected by a pure HIV subtypes/
sub-subtypes, although CRFs may predominate in specific regions (e.g., CRF02_AG in West and West 
Central Africa26).
Because several HIV-1 strains co-circulate at high frequencies in some countries, e.g., Kenya27–29, 
high-risk patients in these regions are frequently infected by more than one subtype/sub-subtype or CRF. 
If a cell is superinfected by HIV-1 virions from different subtypes/sub-subtypes/CRFs30, two viral RNA 
genomes from different subtypes/sub-subtypes/CRFs can be packaged into the same virion in that cell 
(Fig. 1a). After this virion infects the next target cell, RT can generate an inter-subtype unique recom-
binant form (URF) of the HIV-1 subtypes/sub-subtypes/CRFs that can be readily identified (Fig. 1b)31.
Here, we hypothesized that selection favours the outgrowth of inter-subtype URFs in untreated, 
HIV-infected individuals if the URF contains advantageous changes that enable escape from CTL 
responses (Fig. 1c). Thus, we proposed that URFs would be more likely to be selected in hosts with CTL 
responses that are more efficient than average and that these recombinants would be likely to increase 
disease progression. Understanding the interplay between effective CTL responses and HIV-1 evolution 
is critical because these responses are the only anti-HIV immune responses known to be associated 
with delayed disease progression in natural infection6; thus, these responses are likely to be important 
to emulate in an HIV-1 vaccine. Furthermore, URFs have the potential to become CRFs and may have 
a critical effect on vaccine efficacy by increasing the global diversity of HIV-1.
To test our hypothesis, we examined the relationship between the HIV-1 form (homogeneous 
HIV-1 subtype/sub-subtype (HHS) or CRF versus URF), HLA profile and clinical progression rate in 
HIV-infected female commercial sex workers (CSWs) from the Pumwani slum in Nairobi, Kenya, where 
several HIV-1 subtypes and CRFs co-circulate27–29.
Results
HIV subtype distribution and recombination analyses. Approximately 1200 bases spanning the 
HIV-1 p17-p24 region from peripheral blood mononuclear cell (PBMC) DNA samples from each of the 
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113 patients from Pumwani were PCR amplified and sequenced using population sequencing to optimize 
primers followed by single genome amplification of the PBMC DNA and sequencing. The sequences 
were subtyped and each section of the recombinant sequences was annotated with breakpoints using 
jpHMM32.
The following HIV-1 subtypes were prevalent in our cohort: HIV-A1, 61% (69/113); HIV-C, 6% 
(7/113); and HIV-D, 18% (20/113) (Table S1). These results are consistent with other studies in Kenya27,28. 
In addition, 17 women carried recombinant HIV-1 (15%). These recombinant viruses were mixtures 
of HIV-A1 and HIV-C (n = 5) or of HIV-A1 and HIV-D (n = 12); three patients carried additional 
recombinant forms (HIV-A2/HIV-D (ML900), HIV-A1/HIV-A2/HIV-C (ML1765), and HIV-C/HIV-F 
(ML1812)), and two carried recombinants with unique breakpoint patterns (ML1700 and ML2033) 
(Fig. 2a).
To identify women in whom selection had favoured the outgrowth of URFs, we developed an algo-
rithm to distinguish between URFs and any CRFs that had infected the women by chance. This analysis 
was based on an examination of subtype-section specific phylogenetic trees constructed from alignments 
of sequences from this cohort and from the HIV database (as illustrated in Fig. 2b–d and described in the 
Methods). Briefly, we examined each tree sampled from the posterior distribution for every patient with 
recombinant HIV-1. For our assessment of whether a given subtype-section was derived from an HHS 
or a CRF, we assumed that a URF would not recombine again to become an HHS, in contrast to those 
CTL-escape mutations that confer reduced viral fitness and that typically revert following transmission to 
HLA-mismatched recipients (reverting mutations)2,33. Therefore, if a patient’s subtype-section descended 
directly from a phylogenetic tree node that also had HHS descendants, then we estimated that the patient 
was infected with a URF (Fig.  2c) because the parent node of an HHS sequence must also have been 
an HHS. Conversely, if a subtype-section’s parent node had only other recombinant sequences amongst 
its descendants, then we estimated that the patient was infected with a CRF (Fig.  2d). By performing 
this analysis on each tree sampled from the posterior distribution of trees, and bringing together the 
analyses for both segments, we were able to calculate the Bayesian posterior probability that a patient 
was infected by a URF.
Figure 1. Generation of HIV-1 recombinants and recombinant analyses. a. Example of a person infected 
with two HIV-1 subtypes (subtypes X and Y). Infection with the second HIV subtype (superinfection) 
may occur at any time after infection by the first HIV subtype but is most likely to occur during the first 6 
months of initial infection in women18,19,24,25. The two HIV subtypes may infect the same target cell30, which 
can result in the packaging of two different viral RNA genomes into the same virion (highlighted in an 
orange circle, XY). b,c. Examples of infection with the XY virion and of HIV-1 recombination and selection. 
HIV reverse transcriptase (orange dot in the virion, orange line in the diagram) switches templates between 
RNA genome X and RNA genome Y to generate a unique recombinant form of the DNA strand (the 
resulting virion is highlighted in a grey circle, URFxy). Because this recombinant carries the HIV Y escape-
mutation version of a targeted CD8 epitope, it is more fit than HIV X, and because this particular sequence 
combination results in faster replication than HIV Y, it is more fit to replicate and spread in the host than 
any of the parent viruses. Therefore, URFxy eventually dominates the viral population.
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Using the results of the phylogenetic tree and recombinant breakpoint analyses, we estimated that the 
patient most likely carried a URF if 1) both recombinant sequence-sections were derived from HHSs; 2) 
one section was derived from an HHS and the other section was derived from a CRF; or 3) the recom-
binant sequence had a unique breakpoint pattern. Based on this analysis, 15/17 women (88%) were likely 
to carry a URF and 2/17 carried the same CRF (12%) (Table 1). This CRF was similar to a previously 
reported recombinant HIV-1 in the HIV database that was derived from Pumwani (GQ431530); thus, 
this CRF may have been generated and spread locally.
Next, we examined the composition of each URF and found that 6/15 (40%) of the URFs contained 
sections of two HHSs and that 9/15 (60%) contained one section of a local CRF and one section of an HHS 
(Table 1). The latter pattern is consistent with a report of a recombinant HIV with sections of a CRF34.
ML2019
ML2000
ML1852
ML1848
ML1812
ML1765
ML1700
ML1419
ML1347
ML2033
ML1317
ML1128
ML900
ML293
ML199 HIV-A1
HIV-C
HIV-D
HIV-A2
HIV-F
0 200 400 600 800 1000 1200 1400
HIV gag
p17 p24
Recombinant sequences
Subtype X alignment
Homogeneous sequences
stnemges tnanibmoceRstnemges tnanibmoceR
Subtype Y alignment
X Y
Homogeneous sequences
b.
a .
Unique Recombinant Circulating Recombinant
c. d.
(CRF)
(HHS)
R  
(CRF)
R  
(CRF)
(HHS)
(HHS)
R 
(URF)
HHSHHS HHS
Figure 2. Outline of all unique recombinant HIV-1 gag forms. a. Ten women carried one predominant 
URF, whereas five women carried several distinct URFs (ML199, ML900, ML1765, ML1812, ML2033); in 
three cases these URFs incorporated sections from additional HIV-1 subtypes (ML900, ML1765, ML1812). 
Blue = HIV subtype A1 (HIV-A); cyan = HIV subtype A2 (HIV-A2); green = HIV subtype C (HIV-C); 
red = HIV subtype D (HIV-D); yellow = HIV subtype F (HIV-F); and white = gap. A unique breakpoint 
pattern was found in patients ML1700 and ML2033. b. Outline of the construction of sequence alignments. 
Subtype-specific alignments (labelled X and Y) were created by dividing the recombinant sequences into 
subtype-specific sections and using the longest shared subtype-section and matching sections of the HHS 
sequences from the rest of the women in the cohort and sequences from the HIV database. c,d. Outline of 
the subtype-specific Bayesian phylogenetic analysis based on the assumption that a URF will not recombine 
again to become an HHS. Any recombinant patient sequence on the tree whose parent node (yellow circle) 
has an HHS descendant likely is derived from an HHS, which means that the recombinant sequence is 
likely to be a URF (c). If the parent node only has recombinant descendants, then the patient is likely to 
be infected with a CRF (d). The branch on which the recombination event is suspected to have occurred is 
shown in red.
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This overrepresentation of CRF sections in the URF group is highly unlikely to occur by chance 
given the frequency of CRFs in the cohort (2/98 (2%) versus 9/15 (60%), Fisher’s exact test, p < 0.0001; 
odds ratio = 9.8), Thus, our results indicate that local CRFs may have a specific survival advantage in 
the URF group.
Overrepresentation of beneficial HLA-variants in HIV-infected women with URFs. To test our 
hypothesis that unique HIV-1 recombinants are more likely to occur in hosts with CTL responses that are 
more efficient than average, we compared the frequency of HLA variants associated with delayed disease 
progression (HLA-A*7401, HLA-B*1302, HLA-B*14/-Cw8, HLA-B*5701, HLA-B*5702, HLA-B*5703, 
HLA-B*5801 and HLA-B*8101)2,35–37 in the group of women with URFs to that in women with HHSs/
CRFs. These beneficial HLA variants were used as surrogate markers for CTL-responses that were more 
efficient than average because direct analysis of the women’s CTL responses was impossible due to a lack 
of PBMC samples. However, a causal relationship between CTL responses and HIV recombination has 
been demonstrated in one patient19 and HLA variants have been successfully used as surrogate markers 
for CTL-responses in numerous studies, e.g.,38.
Women with beneficial HLA variants (12/52) were over 5 times more likely to carry URFs than those 
without beneficial HLA variants (3/61) (Fisher’s exact test, p < 0.0055; odds ratio 5.7). However, Fisher’s 
exact test is a test of equality of proportion and, with the proportions in question being based upon URF 
classifications derived from Bayes Rule, no account has been taken of the uncertainty in those classifica-
tions. Although strict classification followed by Fisher’s exact test has the virtues of simplicity and ease 
of interpretation, information has been discarded; therefore the analyses were improved by fitting binary 
generalised linear models (GLMs) to the log(odds) of the Bayesian posterior probabilities. Odds ratios 
quoted for these results refer to a change in Bayesian log(odds) of unity, which corresponds to a poste-
rior probability of 0.75; odds-ratios corresponding to a posterior probability of 0.9 can be approximated 
by squaring the quoted odds ratio, and cubing it would correspond to a posterior probability of 0.95. 
This more meticulous approach confirmed that women with beneficial HLA variants were more likely 
to carry URFs than those without (binary GLM, odds ratio = 1.25, p = 0.0107). Likewise we observed a 
significantly higher frequency of beneficial HLA variants in the URF group (12/15, 80%) compared with 
the group with HHSs/CRFs (40/98, 41%) (Fisher’s exact test, odds ratio = 5.7, p = 0.0055; binary GLM, 
odds ratio = 1.25, p = 0.0107).
These results suggest that the efficient CTL responses associated with beneficial HLA variants selects 
for the outgrowth of HIV-1 recombinants.
Beneficial HLA-variants have less beneficial effects on disease progression in HIV-infected 
women with URFs. Next, we investigated whether the relationship between beneficial HLA variants 
 Table 1.  Patients with recombinant HIV-1: Pt ID: unique cohort number; URF MP: URF maximum 
probability; Gag composition hA, hC, hD: homogeneous HIV-A1, HIV-C and HIV-D sections; CRF_A and 
CRF_D: CRF HIV-A1 and CRF HIV-D sections, respectively; CRF_AD: local HIV-A1/HIV-D CRF; URP: 
unique recombinant pattern. The HIV-A1 sections of ML900 were paraphyletic and could not be analysed 
using our algorithm. RF: recombinant form; HLA group: beneficial (B), neutral (N), or detrimental (D); DP: 
disease progression classification.
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and disease progression in the group of women with URFs was similar to that in the group of women 
with either HHSs or CRFs. We used the biannual CD4-counts to classify the patients into groups accord-
ing to clinical progression rate and examined the distribution of beneficial, detrimental and neutral HLA 
variants in each group (LTNPs (HIV-infected for >7 years and stable CD4 counts >400/μ l), long-term 
survivors (HIV-infected for >7 years and stable CD4 counts >200/μ l and <400/μ l), slow progressors 
(HIV-infected for 5–7 years and unstable CD4 counts ≥200/μ l and <400/μ l), standard progressors 
(HIV-infected for 3–5 years and CD4 counts >200/μ l) and rapid progressors (HIV-infected for <3 years 
and CD4 counts <200/μ l)) (Fig. 3).
For both the URF and the HHSs/CRF patient groups, we generated two disease progression (DP) 
groups; one with long-term control of HIV infection (LTNPs and long-term survivors = DP1) and one 
with slow/standard disease progression (slow progressors and standard progressors = DP2); rapid pro-
gressors (n = 2) were not included because these were found only in the HHS/CRF patient group. We 
grouped standard progressors and slow progressors because standard progressors often had CD4 counts 
close to or above 400/μ l, consistent with39, and the slow progressors counts were unstable.
In the group of women with HHSs/CRFs, we compared the frequency of beneficial, neutral and 
detrimental HLA variants in DP1 and DP2 by fitting a binary GLM to the HLA variant using neutral as 
the reference category. We found that beneficial HLA variants predominated in DP1 (binary GLM, odds 
ratio = 3.24, p = 0.0449), whereas no difference was observed between the frequencies of neutral and 
detrimental HLA variants (p = 0.3858) (Fig. 3, Table S1). Thus, in women with HHSs/CRFs, those with 
beneficial HLA variants were over 3 times more likely to have slow disease progression than those with 
neutral or detrimental HLA variants. If we had included the rapid progressors in DP2, then we would 
have obtained a slight increase in power (odds ratio = 3.48, p = 0.0328).
Next, we tested whether the presence of either URFs or HHSs/CRFs affected disease progression in 
patients with beneficial HLA variants, i.e., if the patient would be likely to belong to DP1 or DP2. By 
regressing on the Bayesian log(odds) we found that patients with URFs were marginally more likely 
to be in DP2 and that patients with HHSs/CRFs were slightly more likely to be in DP1 (binary GLM, 
odds-ratio = 1.04, p = 0.0377)(Table S1). Second, we tested if the frequency of beneficial HLA variants 
was similar in patients with either URF or HHSs/CRFs in DP2 and we observed a significantly higher 
frequency of beneficial HLA-variants in the URF group (binary GLM, odds-ratio = 1.26, p = 0.0072).
Collectively, these findings suggest that beneficial HLA variants might have less beneficial effects on 
disease progression in women with URFs than in women with either HHSs or CRFs.
Discussion
Here, we compared the HLA variant distribution and clinical progression rate in groups of HIV-infected 
women with or without unique HIV-1 recombinants. Women with URFs had significantly higher 
Figure 3. HLA variant distribution in clinical progression groups in women with either HHSs/CRFs or 
URFs. a. The number and percentage of HIV-infected women carrying HHSs or CRFs in clinical groups 
with distinct disease progression profiles: long-term non-progressors (LTNPs), long-term survivors (LTSs), 
slow progressors (SLPs), standard progressors (SP) and rapid progressors (RPs). In each group, we indicated 
the distribution of HLA variants associated with delayed disease progression (beneficial HLA-variants), 
standard progression (neutral HLA-variants) or rapid progression (detrimental HLA-variants). b. As in A, 
except using data from the group of women carrying unique recombinant forms of HIV-1.
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frequencies of HLA variants, which were associated with delayed disease progression. In addition, the 
presence of URFs appeared to decrease the beneficial clinical effect of these HLA variants.
URFs could potentially be generated and selected in most CSWs in our cohort because recombi-
nation occurs as a result of the inherent properties of RT, the CSWs likely share the same risk factors, 
and the risk of HIV superinfection for patients with any given HLA variant is similar to that of initial 
infection during the first 6 months and subsequently decreases by approximately half24,25. Thus, the risks 
of HIV superinfection and inter-subtype recombination are probably greatest during acute and very 
early infections, consistent with observations in two patients18,19, but may potentially occur at all disease 
stages. HIV-1-specific cellular immune responses during chronic infection do not appear to significantly 
contribute to protection from HIV-1 superinfection25 and an overrepresentation of beneficial HLA vari-
ants has not been found in patients that were co-infected/superinfected40. The only marker that appears 
to weakly influence the risk of superinfection is the frequency of uninfected CD3+ /CD4+ /CCR5+ T 
cells25. Effective CTL responses may increase the pool of uninfected CD3+ /CD4+ /CCR5+ T cells that 
could be targets for a superinfecting virus, although the findings that CTL activation levels were not 
associated with the frequency of CD3+ /CD4+ /CCR5+ T cells25 and that beneficial HLA variants were 
not overrepresented in patients that were co-infected/superinfected40 do not support this suggestion.
The significant overrepresentation of patients with beneficial HLA variants in the URF group suggests 
that the effective CTL responses in these women selects for the outgrowth of the URFs. Because the URFs 
eventually dominate the viral population, the URFs must be more fit than each of the parent viruses. 
This fitness gain may result from the selection of HIV-1 with en bloc combinations of advantageous 
mutations, and recombination may partly explain why HIV-1 containment fails in approximately 70% of 
patients with beneficial HLA variants within 16 years of infection41.
URFs were observed in 23% of women with beneficial HLA variants. This frequency likely represents 
a near maximum estimate of the frequency of inter-subtype gag recombination in this group because 
the CSWs in our cohort had a very high number of daily customers (an average of 4 men per day) and 
because the epidemic in Kenya is caused by several co-circulating and relatively prevalent HIV-1 sub-
types and CRFs27–29,35. In combination, these factors provide many opportunities for infection with multi-
ple HIV-1 subtypes, inter-subtype recombination, and CTL-driven HIV-1 adaptation to the host-specific 
genetic background.
Despite the limitations of our study (i.e., the limited DNA amount obtained from each woman, which 
constrained the number of analysed Gag copies; the cross-sectional design; the use of HLA variants as 
surrogate markers for CTL responses and the limited number of women), we still obtained statistically 
significant results. However, we likely underestimated the overall URF frequency because some patients 
with homogeneous HIV Gag regions may have viral variants with recombined regions outside Gag. Such 
recombinants were described by Dowling et al., who found that 41% of nearly full-length recombinant 
HIV-1 sequences from Kenya only contained the recombinant sequence in pol and/or env28.
Nevertheless, Gag is likely a key target for CTL-driven selection for recombination because only CTL 
responses against Gag are associated with viral containment and lower mean viral loads6. Thus, HIV-1 
escape from Gag-specific CTL responses would likely be more advantageous for viral survival and spread 
than escape from CTL responses that target other viral proteins.
Although CSW infection with a second HIV-1 (HHS or CRF) may be hampered by factors such as 
anti-HIV immune responses and target cell depletion in the genital tract, it is unclear why most CSWs 
are not infected with multiple HHSs/CRFs given their daily exposure to numerous clients. One possible 
explanation is that any superinfecting HIV-1 has to be more fit initially than the established HHS/CRF, 
which is already adapted to survive in the specific host, and this situation is rarely the case.
The overrepresentation of CRF-sections in HIV recombinants in the URF group suggests that local 
CRFs may have a specific survival advantage in women with beneficial HLA variants, possibly because 
the CRFs arise from URFs generated in this patient group. Alternatively, or additionally, a prior success-
ful recombination could be an indicator of subsequent recombination success possibly because mutations 
in the CRF already compensate for inter-subtype sequence incompatibilities. The potential local CRF 
fitness advantage and/or inherent CRF recombination propensity further amplifies HIV diversification 
in individuals with beneficial HLA variants.
Beneficial HLA variants were frequently found in LTNPs and long-term survivors in the HHS/CRF 
group, whereas beneficial HLA variants were concentrated in slow progressors and standard progres-
sors in the URF group. Thus, the normally protective HLA variants appear to have less of a beneficial 
effect on disease progression in women carrying URFs. The fact that we predominately observed URFs 
in women with beneficial HLA variants who had been infected for a short duration and who were 
progressing faster refutes a key potential source of confounding, namely, that URFs would be overrepre-
sented in HIV-infected women with beneficial HLA variants simply because they are more likely to be 
superinfected because they survive longer than those without beneficial HLA-variants. Our results are 
supported by previous reports demonstrating that superinfection and/or dual infection with two HIV 
strains lead to faster CD4+ T cell decline42 and/or to greater increases in viral load40 in men who have 
sex with men, faster disease progression in a mixed cohort43 and a trend towards accelerated CD4+ T 
cell decline and increased viral load in women, although the effect on clinical progression events in the 
latter study was limited44. However, only one of these studies examined whether recombination occurred 
in the patients’ viral population40 and was not powered to estimate what effect recombination had on 
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disease progression. In combination, these studies and our results suggest that the effect of recombination 
on disease progression needs to be further examined in larger cohorts in which both CD4 counts and 
viral load data are available and transmitted recombinants could be cloned and tested for fitness in vitro.
These results suggest that a balance exists between CTL responses and viral adaptation in most patients 
with protective HLA variants and that the delayed disease progression in these patients is a result of this 
unique virus-host equilibrium. However, this beneficial balance may be disrupted if the CTL response 
results in the outgrowth of highly adapted URFs, and our results suggest that this process limits the 
protective effects of the immune response. Recombination and outgrowth of unique recombinants could 
likewise undermine successful intra-host immune containment of other human and animal retroviruses 
e.g., human T-lymphotropic virus type 1 (HTLV-1)45 and Mink cell focus-forming viruses in mice46.
Our results suggest that individuals with protective HLA variants who engage in any high-risk behav-
iour (e.g., prostitution or intravenous drug use) constitute a hub for HIV-1 diversification that could 
lead to the outgrowth of unique forms of recombinant HIV-1 that have the potential to spread in the 
population. If these new HIV-1 recombinants do spread, then they will contribute to viral diversification 
locally and globally and may lead to faster progression to AIDS and/or to more rapid CD4 decline than 
the homogenous subtypes from which they originated, as observed in, e.g., Guinea-Bissau and Brazil47,48. 
Thus, whereas CTL responses in individuals with protective HLA-variants are beneficial for the individ-
ual, they may be detrimental to the population because they fuel HIV-1 evolution.
These results suggest that monitoring the effect of HIV-vaccination on HIV-1 diversification in 
infected vaccinees may be necessary because a vaccine that elicits effective CTL responses, but that does 
not prevent infection, may increase the formation of URFs and thereby increase viral diversification and 
adaptation to the vaccinated population.
Methods
Study design and participants. We obtained DNA samples extracted from peripheral blood mon-
onuclear cells (PBMC) from 113 HIV-1 infected female CSWs from the Pumwani Sex Worker Cohort35. 
Enrolment in the cohort included a clinical examination, questionnaire and interview completion, HIV-1 
testing, lymphocyte counts and written and oral informed consent. The women are followed biannually 
with blood draws for research studies and lymphocyte counts. All the women in this study were enrolled 
between 1985 and 1995 and the PBMC samples were obtained between 1997 and 2004, before antiret-
roviral drugs were available to the cohort. These women constituted all the women in the Pumwani Sex 
Worker Cohort who fulfilled the following selection criteria: HIV-1 infection, known HIV-1 disease 
progression profile, no antiretroviral treatment, available DNA sample and known HLA type. The inves-
tigators who performed the recombination analyses and allocated the women into groups with different 
HIV-1 forms (HHS, CRF or URF) were blinded to the HLA data and disease progression profiles. The 
comparison between HIV-1 form, HLA profile and clinical progression rate was performed by investiga-
tors who had not allocated the women into the different HIV-1 form groups. This study was conducted 
according to the principles expressed in the Declaration of Helsinki; the National AIDS Committee, the 
National Ethics and Scientific Review Committee of Kenyatta National Hospital and the University of 
Manitoba Use of Human Subjects in Research review committee have approved studies using this cohort.
DNA extraction and HLA typing. PBMC DNA was extracted using QIAamp DNA Mini Kits 
(Qiagen, The Netherlands) and 5–10 μ l of each sample was available for this study. HLA class I genotyp-
ing was performed using multiplex PCR (Dynal Biotech, Norway).
Assignment of HLA variants as “beneficial”, “detrimental” and “neutral”. HLA variants were 
assigned as beneficial, detrimental, and neutral with regard to disease progression based on previously 
published reports2,35–37. Beneficial HLA variants included HLA-A*7401, HLA-B*1302, HLA-B*14/-Cw8, 
HLA-B*5701, HLA-B*5702, HLA-B*5703, HLA-B*5801 and HLA-B*8101. Detrimental HLA variants 
included HLA-B*07, HLA-B*1510, HLA-B*1801, HLA-B*35, HLA-B*53 and HLA-B5802. All other 
HLA variants were labelled as neutral. One patient (ML1317) carried two beneficial (HLA-A*7401 and 
HLA-B*5801) and one detrimental (HLA-B*35) HLA variant and was classified as having an overall 
beneficial HLA profile (Table 1) because we estimated that the beneficial effect was strongest based on 
the HLA-distribution results in the group with HHS/CRF, the co-operative additive effect of beneficial 
HLA variants49–51 and previous reports2,35–38,52. Two patients carried one beneficial and one detrimental 
HLA-variant (ML293: HLA-B*8101/HLA-B*5802, ML2000: HLA-B*7401/HLA-B*5802) and both car-
ried HLA-C*0602. Because HLA-B*5802 was not associated with detrimental effects in this cohort and 
because HLA-C*0602 was significantly associated with a decreased risk of seroconversion, although not 
with slower disease progression35, we estimated that the overall HLA profiles were beneficial (Table 1).
Amplification and sequencing of HIV-1 p24 gag. We amplified ~1200 bases spanning the 
HIV-1 p17–p24 region using a hot-start nested polymerase chain reaction (PCR) (Advantage 2 PCR 
Kit; Clontech). The primers were GAG1 (round 1 (R1)) 728–751, GAG3 (R1) 1941–1916, GAG2 (R2) 
763-788 and GAG4 (R2) 1911–1884 (nucleotide numbers correspond to HIVHXB2 numbering) and 
annealed to regions conserved amongst the subtypes. Because of limited sample availability, we initially 
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performed bulk DNA amplification to optimize the primers and to identify the patients with mixed 
sequence reads. 
Subsequently, we used the PBMC DNA samples to performed single-genome PCR amplification 
of 5–10 genomes per patient, subject to DNA availability. Forward and reverse sequence reads were 
assembled and proofread using Pregap4 and Gap453 and aligned using MacClade (Sinauer Associates) 
(GenBank accession numbers KR781618 - KR782177).
HIV-1 subtyping and analyses of recombinant HIV-1. All HIV-1 sequences were subtyped, 
and each section of the recombinant sequences was annotated with breakpoints and its subtype using 
jpHMM32 (Fig.  2a). The recombinant subtype compositions were also examined using REGA v3.0 
(RegaSubtyping/stanford-hiv/typingtool; as recommended in54), which gave similar results. Because 
REGA does not explicitly infer breakpoints, we used the jpHMM results in subsequent analyses. Two 
patients carried recombinants with unique breakpoints (1700 and 2033) and were classified as URFs. In 
the case of patient ML1700, the breakpoint was outside the p17 and p24 border and combined a homo-
geneous subtype A sequence with a CRF_D HIV. Similar CRF_D HIV fragments were found in other 
recombinants (patients ML1317, ML1852 and ML199); however, in these cases, the recombinant break-
points were found in the p17-p24 border region. In the case of patient 2033, we observed two distinct 
recombinant HIV variants composed of HIV subtype A and HIV subtype C sequence segments. These 
variants had multiple additional breakpoints outside the p17-p24 border. These patterns were unique to 
this patient, and the presence of two related, but distinct, recombinants forms of HIV subtype A and HIV 
subtype C suggested that the recombination events had occurred in this patient. In the other patients, the 
breakpoints between subtypes in the conserved p17-p24 border region were too close to classify them as 
URFs based on the position of the recombination breakpoint (shaded area in Fig. 2a).
To identify women in whom selection had favoured the outgrowth of URFs, we developed a novel 
phylogenetic algorithm that did not rely on breakpoint patterns to distinguish between URFs and any 
CRFs that had infected the women by chance. We only used single recombinants (i.e., sequences with 
one breakpoint) because we needed the longest alignments possible to ensure adequate power in our 
phylogenetic analyses. Briefly, we constructed separate alignments for each subtype; these alignments 
consisted of 1) the subtype sections of the recombinant sequences, 2) matching sections of the HHS 
sequences from our cohort, and, 3) matching sections of the most similar sequences in the HIV database 
(www.hiv.lanl.gov), as determined by BLASTn55 using 1) and 2) as query sequences (Fig.  2b, Table S1, 
Table S2). Because HIV-1 recombinants with HIV-C had two distinct breakpoints, we constructed two 
alignments for this subtype. The recombinant sequences had to be split, and each subtype-section had to 
be analysed in the context of sequences from the same subtype, because each subtype-section in a given 
recombinant will have a separate evolutionary history, which is highly likely to confound the analysis if 
the recombinant sequence is included as a whole.
We used Bayesian inferential techniques (MrBayes56) to build separate posterior distributions of phy-
logenies from each of the subtype alignments (HIV-A1 and HIV-C: model K80 + G; HIV-D: model 
GTR + G). We ran four replicates per analysis for 50 M steps each and confirmed convergence in 
TRACER. Because the sequences were short and relatively conserved, we were unable to construct max-
imum clade credibility trees from the posterior trees with sufficient support values on the internal nodes 
to make URF/CRF calls. Instead, we used a novel algorithm to infer the posterior probability that a 
patient was infected with a URF directly from the trees sampled from the posterior tree distribution.
We assumed that an inter-subtype recombinant HIV would not recombine again to become an HHS. 
From this assumption follows that the parent node of any HHS sequence must also be an HHS sequence. 
Therefore, any tree in which a recombinant sequence has an HHS sister sequence supports the hypothesis 
that the recombinant sequence is a URF because it is derived from an HHS parent node (Fig. 2c), which 
would occur if a patient were infected with a homogenous subtype that then recombined within the host 
to form the URF. Conversely, a recombinant sequence that has another patient’s recombinant sequence as 
its sister sequence is evidence that both those recombinant sequences are CRFs (Fig. 2d).
Thus, for each tree sampled from the posterior tree distribution derived from a subtype-section align-
ment (consisting of subtype-sections of recombinant sequences, matching sections from homogenous 
sequences, and matching sequences from the LANL database) we examined whether the tree supported 
the URF hypothesis or the CRF hypothesis for each patient. For every patient infected with a recom-
binant, we identified the common ancestor of the patient’s subtype-section sequences in the tree. If the 
sequences from that patient were monophyletic (i.e., the common ancestor of the patient’s sequences had 
descendants from that patient exclusively), then we selected the sequences’ common ancestor’s parent 
node to assess the recombinant form. If the patient’s sequences were paraphyletic (i.e., the common 
ancestor of the patient’s sequences had sequences from other patients amongst its descendants), then 
we selected the common ancestor of the patient’s subtype-section sequences. If the selected node had an 
HHS from another patient amongst its descendants, then we interpreted the tree as evidence that an HHS 
had infected the patient and that this HHS had subsequently recombined in the patient to form a URF 
(Fig. 2c). Conversely, if the selected node only had recombinant sequences amongst its descendants, then 
we interpreted the tree as evidence that the patient had been infected by a CRF (Fig. 2d).
To ensure that rooting effects did not confound the analysis, we rooted each tree sampled from the 
posterior distribution on a random sequence from a random HHS-infected patient and excluded patients 
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for that tree whose sequences were too close to the root, i.e., when the selected node had more than four 
different patient/virus combinations as its descendants. For each patient, we calculated the probability 
that their sequences in this subtype-section alignment were part of a URF (URF-probability) by dividing 
the number of trees supporting the hypothesis that the patient was infected with a URF (Fig. 2c) by the 
number of trees that were not excluded due to rooting effects. Thus, we were able to interrogate the data 
directly and to integrate over the phylogenetic uncertainty that prevented us from building interpretable 
trees.
We implemented this algorithm in a Python script using the ete2 tree manipulation module57, discard-
ing the first 25% of trees as a burn-in. All analyses were performed separately for each subtype-specific 
alignment, with the results for each patient’s two subtype-sections only brought together immediately 
before performing the downstream statistical analysis. URFs can be composed of a fragment derived from 
a CRF virus joined to a fragment derived from an HHS virus, in which case only the subtype-specific 
analysis containing the HHS-derived fragment would report the appropriate URF probability. Therefore 
we only used the higher of the two URF probabilities for every patient when combining the results 
from the two subtype section analyses performed for that patient. Because no previous analyses of this 
sort have been done, it was not possible to use an informative prior. The results were expressed as the 
Bayesian posterior probability that the recombinant HIV sequences in a given patient was a URF (URF 
maximum probability (MP) in Table 1), and Bayes’ rule was used for classification into HHSs or CRFs 
(Table 1).
Statistical analyses. Equality of proportion was tested with Fisher’s exact test. Where we incorpo-
rated the uncertainty of the Bayesian sequence analysis, binary GLMs were fitted using the posterior 
Bayesian log(odds) as an explanatory variable; these values were calculated from the highest Bayesian 
posterior probabilities of the subtype-sections of a given recombinant HIV-1 (the “URF MP”, Table 1). 
The two recombinant sequences with unique breakpoint patterns were given a URF probability of a 100. 
Binary GLMs were also used for comparing the frequency of beneficial, neutral and detrimental HLA 
variants in DP1 and DP2. All statistical analyses were performed using the R statistical package (version 
3.0.0); p < 0.05 was considered significant.
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